# Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

> **NCT00010218** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 55 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** karenitecin

## Key facts

- **NCT ID:** NCT00010218
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2003-04
- **Final completion:** 2006-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2016-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010218, "Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00010218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*